Cybin (HELP) Return on Sales (2020 - 2024)

Cybin (HELP) posted quarterly Return on Sales of 0.0% for Q4 2024, up 2.22% on a QoQ basis from 0.0% in Q1 2024.

Cybin (HELP) Return on Sales (2020 - 2024) Analysis & Trends

Cybin (HELP) has reported Return on Sales for 3 consecutive years, with 0.0% the latest figure, recorded in Q4 2024.

Quarterly Return on Sales changed N/A year-over-year to 0.0% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.0% (changed N/A YoY) and the FY2021 annual result came in at 282.14%, changed N/A from the prior year.
Return on Sales grew to 0.0% in Q4 2024 per HELP's latest filing, from 0.0% in the prior quarter.
Over the last five years, Return on Sales for HELP reached as high as 2314763.66% in Q2 2020 and fell as low as 0.0% in Q1 2024.
A 3-year average of 578690.91% and a median of 0.0% in 2021 frame the typical range for Return on Sales.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.00%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	0.00%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Cybin	28.04 Mn	28.04 Mn	-	-

Download Data